-
公开(公告)号：EP1065269A4
公开(公告)日：2003-04-09
申请号：EP99906488
申请日：1999-02-25
IPC分类号： A61K38/00 , C07K14/47 , C07K14/705 , C07K16/30 , C12N15/12 , A01K67/00 , C07K14/00 , C07K14/82 , C12N5/16 , C12N15/85 , C12P21/02
CPC分类号： C07K14/4748 , A01K2217/05 , A61K38/00 , C07K14/705 , C07K16/3061
摘要： A genomic DNA encoding the amino acid sequence represented by SEQ ID NO:2 and consisting of 4 exons and 3 introns connecting the same, and a splicing variant of this genomic DNA; and a DNA having a base sequence represented by SEQ ID NO:4 and having a promoter activity, a fragment thereof and utilization of the same.
-
12.发明公开GPC3-TARGETED THERAPEUTIC AGENT FOR ADMINISTRATION TO PATIENTS FOR WHOM GPC3-TARGETED THERAPEUTIC AGENT THERAPY IS EFFECTIVE 审中-公开GPC3 ANZIELENDES治疗剂与GPC3的靶向治疗的患者治疗手段的行政管理
公开(公告)号：EP2937697A4
公开(公告)日：2016-07-13
申请号：EP13864465
申请日：2013-12-24
发明人： OHTOMO TOSHIHIKO , AMANO JUN , NAKAMURA MIKIKO
IPC分类号： G01N33/574 , A61K39/395 , A61K45/00 , A61P1/16 , A61P35/00 , C07K16/30 , G01N33/48 , G01N33/53
CPC分类号： G01N33/57438 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/28 , C07K16/303 , C07K2317/34 , C07K2317/73 , G01N2333/4722 , G01N2400/00 , G01N2800/52
摘要： The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.
-
13.发明公开METHOD FOR SCREENING COMPOUND INHIBITING SIGNAL TRANSDUCTION OF INFLAMMATORY CYTOKINE 有权用于筛选的炎性细胞因子抑制其信号转化合物的
公开(公告)号：EP1127944A4
公开(公告)日：2004-12-29
申请号：EP99949347
申请日：1999-10-21
IPC分类号： A61K38/00 , C07K14/47 , C12N9/12 , C12Q1/48 , G01N33/573 , A61K45/00 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/53 , G01N33/564 , G01N33/577
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/47 , C12Q1/48 , G01N33/573 , G01N2500/02
摘要： By inhibiting the signal transduction of TAK1, effects of inflammatory cytokines are depressed, the production of inflammatory cytokines (IL-1, TNF, etc.) induced by inflammatory stimulus is depressed and the production of other inflammatory cytokines (IL-6, etc.) induced by the inflammatory cytokines is depressed.
-
公开(公告)号：EP1327680A4
公开(公告)日：2004-09-08
申请号：EP01978851
申请日：2001-10-22
IPC分类号： C07K16/24 , C07K16/28 , C12N15/09 , A61K39/395 , C12N15/62
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/24 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2319/00
摘要： A modified antibody containing at least two H chain V domains and at least two L chain V domains of a monoclonal antibody which transduces a signal into cells by crosslinking a TPO receptor to thereby exert TPO agonism. Because of being usable as a TPO signal transduction agonist, this modified antibody is useful as a preventive and/or a remedy for blood diseases in which platelet reduction participates, thrmobopenia following chemotherapy for cancer or leukemia, etc.
-
-
-
搜索结果
14 条记录 (耗时 0.013 秒)
